Literature DB >> 10626794

Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs.

T Ueda1, H Sasaki, Y Kuwahara, M Nezu, T Shibuya, H Sakamoto, H Ishii, K Yanagihara, K Mafune, M Makuuchi, M Terada.   

Abstract

The K-sam gene was first identified as an amplified gene from human gastric cancer cell line KATOIII, and its product is identical to fibroblast growth factor receptor 2. The K-sam gene is located on human chromosome 10q26 and is preferentially amplified in the poorly differentiated types, especially in the scirrhous type, of gastric cancers. During the course of studies on the structural characterization of the amplification units, we found that the carboxyl-terminal exons of K-sam were deleted in three of four of the scirrhous type of gastric cancer cell lines. These deletions generate preferential expression of mRNAs encoding K-sam proteins lacking the carboxyl-terminal region containing the tyrosine residues at positions 780, 784, and 813. The carboxyl-terminal region has been reported to have a sequence required for the inhibition of NIH3T3 transformation, indicating that cells with amplification of the truncated K-sam gene have a growth advantage during the carcinogenic process for the scirrhous type of gastric cancers. This is the first report showing the deletion of the carboxyl-terminal exons of the receptor-type of the protein tyrosine kinase gene. Sequence analysis of the DNA sequences surrounding the deletion junctions shows the presence of unique sequences and indicates the involvement of short homology-mediated recombination in the generation of these deletions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626794

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Authors:  Daniel Zingg; Jinhyuk Bhin; Julia Yemelyanenko; Sjors M Kas; Frank Rolfs; Catrin Lutz; Jessica K Lee; Sjoerd Klarenbeek; Ian M Silverman; Stefano Annunziato; Chang S Chan; Sander R Piersma; Timo Eijkman; Madelon Badoux; Ewa Gogola; Bjørn Siteur; Justin Sprengers; Bim de Klein; Richard R de Goeij-de Haas; Gregory M Riedlinger; Hua Ke; Russell Madison; Anne Paulien Drenth; Eline van der Burg; Eva Schut; Linda Henneman; Martine H van Miltenburg; Natalie Proost; Huiling Zhen; Ellen Wientjens; Roebi de Bruijn; Julian R de Ruiter; Ute Boon; Renske de Korte-Grimmerink; Bastiaan van Gerwen; Luis Féliz; Ghassan K Abou-Alfa; Jeffrey S Ross; Marieke van de Ven; Sven Rottenberg; Edwin Cuppen; Anne Vaslin Chessex; Siraj M Ali; Timothy C Burn; Connie R Jimenez; Shridar Ganesan; Lodewyk F A Wessels; Jos Jonkers
Journal:  Nature       Date:  2022-08-10       Impact factor: 69.504

Review 2.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

3.  High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Authors:  Alex Pearson; Elizabeth Smyth; Irina S Babina; Maria Teresa Herrera-Abreu; Noelia Tarazona; Clare Peckitt; Elaine Kilgour; Neil R Smith; Catherine Geh; Claire Rooney; Ros Cutts; James Campbell; Jian Ning; Kerry Fenwick; Amanda Swain; Gina Brown; Sue Chua; Anne Thomas; Stephen R D Johnston; Mazhar Ajaz; Katherine Sumpter; Angela Gillbanks; David Watkins; Ian Chau; Sanjay Popat; David Cunningham; Nicholas C Turner
Journal:  Cancer Discov       Date:  2016-05-13       Impact factor: 39.397

4.  FGFR2 gene amplification and clinicopathological features in gastric cancer.

Authors:  K Matsumoto; T Arao; T Hamaguchi; Y Shimada; K Kato; I Oda; H Taniguchi; F Koizumi; K Yanagihara; H Sasaki; K Nishio; Y Yamada
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

Review 5.  Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.

Authors:  Kai Hung Tiong; Li Yen Mah; Chee-Onn Leong
Journal:  Apoptosis       Date:  2013-12       Impact factor: 4.677

6.  Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.

Authors:  Hideki Yamaguchi; Miho Takanashi; Nachi Yoshida; Yuumi Ito; Reiko Kamata; Kiyoko Fukami; Kazuyoshi Yanagihara; Ryuichi Sakai
Journal:  Cancer Sci       Date:  2014-03-24       Impact factor: 6.716

7.  The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study.

Authors:  Yong-Xu Jia; Teng-Fei Li; Dan-Dan Zhang; Zong-Min Fan; Hui-Jie Fan; Jie Yan; Li-Juan Chen; Hong Tang; Yan-Ru Qin; Xing-Ya Li
Journal:  Onco Targets Ther       Date:  2016-09-27       Impact factor: 4.147

8.  ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.

Authors:  Aya Kikuchi; Tomoyuki Suzuki; Taisuke Nakazawa; Masateru Iizuka; Ayako Nakayama; Tohru Ozawa; Minoru Kameda; Nobuaki Shindoh; Tadashi Terasaka; Masaaki Hirano; Sadao Kuromitsu
Journal:  Cancer Sci       Date:  2017-02       Impact factor: 6.716

9.  Identification of candidates for driver oncogenes in scirrhous-type gastric cancer cell lines.

Authors:  Eirin Sai; Yoshiyuki Miwa; Reina Takeyama; Shinya Kojima; Toshihide Ueno; Masakazu Yashiro; Yasuyuki Seto; Hiroyuki Mano
Journal:  Cancer Sci       Date:  2019-07-15       Impact factor: 6.716

10.  Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.

Authors:  Jinyan Du; Paula Bernasconi; Karl R Clauser; D R Mani; Stephen P Finn; Rameen Beroukhim; Melissa Burns; Bina Julian; Xiao P Peng; Haley Hieronymus; Rebecca L Maglathlin; Timothy A Lewis; Linda M Liau; Phioanh Nghiemphu; Ingo K Mellinghoff; David N Louis; Massimo Loda; Steven A Carr; Andrew L Kung; Todd R Golub
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.